Genetic Therapy Inc. has supplied retroviral vectors to a Frenchtrial of gene transfer.
Doctors at Centre Leon are analyzing the ability of tumorinfiltrating lymphocytes to find tumors and to see how long thecells persist in the body.
The French strategy is similar to that performed at the NationalInstitutes of Health in patients with metastatic melanoma. TheGaithersburg, Md., company provided the vectors for thoseexperiments as well, and has supplied vectors in every humantrial of gene transfer approved so far.
The company's stock (NASDAQ:GTII) closed at $15, up $1 onFriday.
(c) 1997 American Health Consultants. All rights reserved.